Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | 1.23% | 89.07 | 1.3% | $885.86m | |
| AMGN | Amgen Inc. | 0.09% | 191.49 | 1.2% | $554.58m | |
| GILD | Gilead Sciences, Inc. | 0.72% | 65.49 | 0.9% | $453.28m | |
| ONCE | Spark Therapeutics, Inc. | -0.25% | 113.67 | 11.2% | $443.24m | |
| BIIB | Biogen Inc. | -0.58% | 323.76 | 1.3% | $352.26m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.15% | 406.99 | 2.6% | $278.79m | |
| ILMN | Illumina, Inc. | 1.61% | 310.70 | 3.5% | $273.06m | |
| BPTH | Bio-Path Holdings, Inc. | -9.32% | 25.20 | 190.1% | $257.65m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -3.05% | 181.76 | 1.9% | $239.61m | |
| SRPT | Sarepta Therapeutics, Inc. | -0.28% | 126.47 | 15.4% | $205.98m | |
| EXAS | Exact Sciences Corporation | -0.85% | 91.15 | 25.3% | $189.71m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.43% | 132.94 | 2.0% | $178.02m | |
| A | Agilent Technologies, Inc. | 0.28% | 81.20 | 1.6% | $151.29m | |
| IONS | Ionis Pharmaceuticals, Inc. | 0.11% | 79.61 | 8.3% | $101.25m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.06% | 91.44 | 4.3% | $95.59m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.